Biography for John Carroll
John D. Carroll, Editor-in-Chief
John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Here's a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they were really, really bad at drug development.
The billions of dollars raised on the market in IPOs and secondary offerings has been bankrolling an expanding amount of development work at companies around the world. For biotech, these are the days.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
Billions of dollars in new biotech investments are being made, R&D is being globalized more than ever before and new technologies and drug classes are moving fast through the clinic. FierceBiotech assesses what we believe are the 5 top trends to watch in the year ahead.
An upstart biotech based in Bermuda says that it has in-licensed an Alzheimer's drug from GlaxoSmithKline and plans to take it into Phase III studies next year.
The J&J Innovation center in California has helped orchestrate a deal with San Diego-based Sevion Therapeutics to develop new antibodies for a Janssen affiliate, CNA Development.
Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.
Bristol-Myers Squibb has won a pioneering FDA approval for Opdivo (nivolumab), its top therapeutic asset in the pipeline, as a new therapy for melanoma.
Cambridge, MA-based ImmusanT has raised $12 million to back its midstage program for a new peptide-based therapeutic vaccine to combat celiac disease.
BioCryst Pharmaceuticals won its first-ever FDA approval for a new treatment and subsequently saw its shares slide as analysts yawned over its sales potential.